Deck 36: Epidemiology of Lymphoma

Question 1

During 2018, 509,590 new cases of non-Hodgkin's lymphoma were diagnosed in the world population, and 248,724 individuals died from the disease.

Answer 1

True

Question 2

Nearly 75% of deaths from lymphoma occur after the age of 65 years.

Answer 2

True

Question 3

Age-adjusted rates of non-Hodgkin's lymphoma dramatically increased in the United States population during the period 1970-1995.

Answer 3

True

Question 4

The annual incidence of non-Hodgkin's lymphoma in the United States increased until about 1995 but then subsequently declined, coinciding with the decline in rates of HIV disease.

Question 5

Two principal biological phenomena involved in the genesis of lymphoma are immunosuppression and antigenic stimulation of lymphocytes.

Question 6

Familial lymphomas are common and account for more than 25% of all cases.

Question 7

Lymphomas are genetically characterized by the presence of heritable chromosomal translocations.

Question 8

The extraordinarily high risk for the development of non-Hodgkin's lymphoma among individuals who are HIV-seropositive has led to its recognition as an AIDS-defining condition.

Question 9

Epstein Barr Virus (EBV) is detected in nearly all cases of Burkitt's lymphoma.

Question 10

The Reed-Sternberg cell of Hodgkin's disease is derived from macrophages.

Question 11

Hodgkin's disease is characterized by the presence of what cells?

A) Reed-Sternberg cells
B) Lymphoblasts
C) Eosinophils
D) Macrophages

Question 12

Multiple myeloma is a malignancy of what cell population?

A) Immature B lymphocytes
B) T lymphocytes
C) Plasma cells
D) Macrophages

Question 13

What ethnic population has the highest rates of multiple myeloma in the world?

A) Caucasian Americans
B) African Americans
C) Hispanic Americans
D) Asian Americans

Question 14

What gene has been found to increase the risk of multiple myeloma among African Americans by more than 5-fold?

A) Mutant P53
B) Mutant BRCA-1
C) Mutant BRCA-2
D) HLA-Cw2

Question 15

What biomarker shows value as a biomarker of impending multiple myeloma?

A) Carcinoembryonic Antigen (CEA)
B) Alpha-Fetoprotein
C) Monoclonal Gammopathy of Undetermined Significance (MGUS)
D) C Reactive Protein (CRP)

Question 16

Waldenström's macroglobulinemia is a rare condition characterized by a monoclonal gammopathy of:

A) immunoglobulin M (IgM).
B) immunoglobulin A (IgA).
C) immunoglobulin G (IgG).
D) undetermined significance (MGUS).

Question 17

The trisomy of Burkitt's lymphoma includes all of the following except:

A) malaria.
B) EBV infection.
C) c-myc translocation to one of the immunoglobulin loci.
D) HIV disease.

Question 18

All of the following groups of patients have high rates of non-Hodgkin's lymphoma except:

A) patients with HIV infection.
B) post-transplant patients treated with immunosuppressive drugs.
C) patients with autoimmune conditions or cancer who received immunosuppressive chemotherapy.
D) patients taking NSAIDs.

Question 19

What percentage of non-Hodgkin's lymphomas are derived from B lymphocytes?

A) 50-60%
B) 60-70%
C) 70-80%
D) 80-90%

Question 20

The highest mortality rates from non-Hodgkin's lymphoma are observed in the populations of:

A) North America.
B) South America.
C) Central Africa.
D) South East Asia.

Question 21

Describe the different forms of lymphoma.

Question 22

Briefly discuss the global epidemiology of non-Hodgkin's lymphoma.

Question 23

Describe risk factors for non-Hodgkin's lymphoma.

Question 24

Describe the trisomy of Burkitt's lymphoma.

Question 25

Discuss the global epidemiology of Hodgkin's lymphoma.

Question 26

Discuss the characteristic features of multiple myeloma.

Question 27

Discuss the global epidemiology of multiple myeloma.

Question 28

Define and discuss Waldenström's macroglobulinemia.

Question 29

Describe strategies for the prevention of lymphoma.

Question 30

Describe new developments in the treatment of lymphoma.